Axcan files Photofrin sNDA for Barrett’s esophagus
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Axcan supplemental NDA for Photofrin (porfimer photodynamic therapy) for treatment of high-grade dysplasia associated with Barrett's esophagus is granted orphan drug status. The filing is based on a 208-patient Phase III study showing ablation of dysplasia in 72% of patients using Photofrin plus oral omeprazole (AstraZeneca's Prilosec) vs. 31% for omeprazole alone (p<0.0001). A trend toward reduction of progression to esophageal cancer was also seen, with a 9.4% progression rate for Photofrin plus omeprazole vs. 18.6% for omeprazole. Photofrin is currently approved for use in esophageal, lung and bladder cancer
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.